Dataset from A Multicentre, 8-week, Single-arm, Open-label, Pragmatic Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adult Subjects With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic (Aripiprazole, Olanzapine, Quetiapine, or Risperidone)

Digital medicine systems (DMS) have been designed to assist individuals with the management
of their daily health, wellness, and medication use. The DMS is being developed as a
healthcare management tool to precisely measure medication adherence and to potentially
enhance adherence.